Johnson & Johnson (JNJ) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $2.59
- Estimate
- $2.52
- Surprise
- +2.7%
- Score at report (before → after)
- 5.3 → 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Johnson & Johnson (JNJ) beat the $2.52 estimate with adjusted EPS of $2.59 — a modest 2.7% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.3/10) to Hold at 5.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates JNJ Hold at 5.5/10.
3 of the last 4 quarters beat the estimate; this quarter's +2.7% surprise compares with a +1.3% four-quarter average.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.3 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Analyst target reached - limited upside remaining
- Weak growth
- Target reached (1.3% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $248.61
- Price target
- $251.84
- Stop
- $237.81
- Upside to target
- +1.3%
- Reward-to-risk
- 0.3:1
The stock trades at 28.8× trailing but 20.9× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 2.2× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
JNJ at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $599.12B
- P/E (fwd)
- 20.9
- P/E (ttm)
- 28.8
- 52-week range
- $184.66–$281.07
- Off 52-week high
- 11.5%
- RSI (14)
- 30
- Volume vs avg
- 2.23×
- Score today
- 5.5/10